Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluating the Safety and Efficacy of AMG531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura(ITP)
This study has been completed.
Study NCT00111475   Information provided by Amgen

First Received on May 20, 2005.   Last Updated on November 20, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Idiopathic Thrombocytopenic Purpura
Additional conditions recognized in this trial
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
More general conditions related to this trial
Autoimmune Diseases
Blood Coagulation Disorders
Blood Platelet Disorders
Hematologic Diseases
Hemorrhage
Hemorrhagic Disorders
Immune System Diseases
Pathologic Processes
Signs and Symptoms
Skin Manifestations
Thrombocytopenia
Thrombotic Microangiopathies
Interventions listed in this trial
AMG 531
Sponsors listed in this trial
Amgen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services